1. Generics Bulletin
  2. >>Products
  3. >>Generics

Mark Cuban’s Generics Company Launches Online Pharmacy

Imatinib, Mesalamine And Colchicine Highlighted For ‘Striking Savings’

 
• By Akriti Seth

Mark Cuban’s generics venture has launched its online pharmacy in the US, highlighting in particular three products – imatinib, mesalamine and colchicine – that it says “epitomize the pharmacy’s striking savings.”

savings
MCCPDC has highlighted three affordable generic drugs • Source: Alamy

Billionaire Mark Cuban’s recent generics venture, Mark Cuban Cost Plus Drug Company, has launched its online pharmacy [www.costplusdrugs.com] in the US, highlighting three drugs – imatinib, mesalamine and colchicine – that it says “epitomize the pharmacy's striking savings”.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

More from Products